The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Open accessAbstract
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USAAbstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.Keywords: memantine, Alzheimer’s disease, dementia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients taking memantine experience adverse effects like fatigue, pain, confusion, urinary incontinence, urinary tract infection, peripheral edema, etc. [35].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P., & Lipton, S. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7162 · Cited by 1,958
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Chen, H., Pellegrini, J. W., Aggarwal, S., Lei, S., Warach, S. J., Jensen, F., & Lipton, S. A. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 628
β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
Koh, J., Yang, L. L., & Cotman, C. W. (1990) · Brain Research · doi:10.1016/0006-8993(90)91355-k · Cited by 617
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Post Stroke Pain: Identification, Assessment, and Therapy
Harrison, R. A., & Field, T. S. (2015) · Cerebrovascular Diseases · doi:10.1159/000375397 · Cited by 434
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Molecular basis of glutamate toxicity in retinal ganglion cells
Sucher, N. J., Lipton, S. A., & Dreyer, E. B. (1997) · Vision Research · doi:10.1016/s0042-6989(97)00047-3 · Cited by 375
Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000224350.82719.83 · Cited by 308
Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine.
Vorwerk, C. K., Lipton, S. A., Zurakowski, D., Hyman, B. T., Sabel, B. A., & Dreyer, E. B. (1996) · PubMed · Cited by 283
Harkany, T., Ábrahám, I. M., Timmerman, W., Laskay, G., Tóth, B., Sasvári, M., Kónya, C., Sebens, J. B., Korf, J., Nyakas, C. J., et al. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00164.x · Cited by 283
Chen, H., & Lipton, S. A. (1997) · The Journal of Physiology · doi:10.1113/jphysiol.1997.sp021909 · Cited by 282
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials
Winblad, B. G., Jones, R. W., Wirth, Y., Stöffler, A., & Möbius, H. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102568 · Cited by 257
Dextromethorphan and Memantine in Painful Diabetic Neuropathy and Postherpetic Neuralgia
Sang, C. N.-M., Booher, S. L., Gilron, I., Parada, S., & Max, M. B. (2002) · Anesthesiology · doi:10.1097/00000542-200205000-00005 · Cited by 254
Wilcock, G. K., Ballard, C. G., Cooper, J. A., & Loft, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0302 · Cited by 253
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
Cummings, J. L., Schneider, E., Tariot, P. N., & Graham, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000223333.42368.f1 · Cited by 227
Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007) · Journal of Child Neurology · doi:10.1177/0883073807302611 · Cited by 221
Gauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Gauthier, S. G., Wirth, Y., & Möbius, H. J. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1341 · Cited by 209
Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., & Parsons, C. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01872-9 · Cited by 200
Calcium, free radicals and excitotoxins in neuronal apoptosis
Lipton, S. A., & Nicotera, P. (1998) · Cell Calcium · doi:10.1016/s0143-4160(98)90115-4 · Cited by 189
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg, ., Doody, R. S., Stöffler, A., Schmitt, F. A., Ferris, S. H., & Möbius, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.49 · Cited by 183
van Dyck, C. H., Tariot, P. N., Meyers, B. S., & Resnick, E. M. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318065c495 · Cited by 182
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
Volbracht, C., van Beek, J., Zhu, C., Blomgren, K., & Leist, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04787.x · Cited by 175
Schifitto, G., NAVIA, B. A., Yiannoutsos, C. T., Marra, C. M., Chang, L., Ernst, T. M., Jarvik, J. G., Miller, E. N., Singer, E. J., Ellis, R. J., et al. (2007) · AIDS · doi:10.1097/qad.0b013e32813384e8 · Cited by 168
Nikolajsen, L., Gottrup, H., Kristensen, A. D., & Jensen, T. S. (2000) · Anesthesia & Analgesia · doi:10.1097/00000539-200010000-00036 · Cited by 162
Maier, C., Dertwinkel, R., Mansourian, N., Hosbach, I., Schwenkreis, P., Senne, I., Skipka, G., Zenz, M. W., & Tegenthoff, M. (2003) · Pain · doi:10.1016/s0304-3959(02)00456-6 · Cited by 153
Merello, M., Mi, N., Cammarota, Á., & Leiguarda, R. C. (1999) · PubMed · Cited by 152
Congenital nystagmus: Randomized, controlled, double‐masked trial of memantine/gabapentin
McLean, R., Proudlock, F. A., Thomas, S., Degg, C., & Gottlob, I. (2007) · Annals of Neurology · doi:10.1002/ana.21065 · Cited by 146
Schley, M. T., Töpfner, S., Wiech, K., Schaller, H.-E., Konrad, C., Schmelz, M., & Birbaumer, N. (2006) · European Journal of Pain · doi:10.1016/j.ejpain.2006.03.003 · Cited by 138
Zeevalk, G. D., & Nicklas, W. J. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08430.x · Cited by 138
Bakchine, S., & Loft, H. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11409 · Cited by 135
Rao, V. L. R., Dog⫧an, A., Todd, K. G., Bowen, K. K., & Dempsey, R. J. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02617-8 · Cited by 135
The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans
Bisaga, A. M., Comer, S. D., Ward, A. S., Popik, P., Kleber, H. D., & Fischman, M. W. (2001) · Psychopharmacology · doi:10.1007/s002130100739 · Cited by 130
Wiech, K., Kiefer, R. T., pfner, S. T., Preissl, H. T., Braun, C., Unertl, K. E., Flor, H., & Birbaumer, N. (2004) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000096002.53818.bd · Cited by 119
Muhonen, L. H., Lönnqvist, J. K., Juva, K., & Alho, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0308 · Cited by 118
An open-label, flexible-dose study of memantine in major depressive disorder
Ferguson, J. M., & Shingleton, R. N. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180314ae7 · Cited by 113
Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells
Bresink, I., Benke, T. A., Collett, V. J., Seal, A., Parsons, C. G., Henley, J. M., & Collingridge, G. L. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15971.x · Cited by 102
Memantine in the Preventive Treatment of Refractory Migraine
BIGAL, M. E., Rapoport, A. M., Sheftell, F. D., Tepper, D., & Tepper, S. J. (2008) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2008.01083.x · Cited by 101
A Pilot Double‐Blind Treatment Trial of Memantine for Alcohol Dependence
Evans, S. M., LEVIN, F. R., Brooks, D. J., & Garawi, F. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00360.x · Cited by 101
Culmsee, C., Junker, V., Kremers, W., Thal, S. C., Plesnila, N., & Krieglstein, J. (2004) · Stroke · doi:10.1161/01.str.0000125855.17686.6d · Cited by 101
A pilot study of the clinical efficacy and safety of memantine for Huntington's disease
Ondo, W. G., Mejia, N. I., & Hunter, C. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.08.005 · Cited by 100
Wenk, G. L., Danysz, W., & Mobley, S. L. (1995) · European Journal of Pharmacology Environmental Toxicology and Pharmacology · doi:10.1016/0926-6917(95)00028-3 · Cited by 98
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease
Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., & Gerlach, M. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_14 · Cited by 98
A 6‐month, open‐label study of memantine in patients with frontotemporal dementia
Diehl‐Schmid, J., Förstl, H., Perneczky, R., Pohl, C., & Kurz, A. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1973 · Cited by 95
Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine
Ridha, B. H., Josephs, K. A., & Rossor, M. N. (2005) · Neurology · doi:10.1212/01.wnl.0000172351.95783.8e · Cited by 92
Schneider, E., Fischer, P.-A., Clemens, R., Balzereit, F., Fünfgeld, E. W., & Haase, H.-J. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1069311 · Cited by 90
Delayed administration of memantine prevents N‐methyl‐ D ‐aspartate receptor‐mediated neurotoxicity
Pellegrini, J. W., & Lipton, S. A. (1993) · Annals of Neurology · doi:10.1002/ana.410330414 · Cited by 89
Wilkinson, D. G., & Andersen, H. F. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105162 · Cited by 87
Stieg, P. E., Sathi, S., Warach, S. J., Le, D. A., & Lipton, S. A. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00214-9 · Cited by 80
Findling, R. L., McNamara, N., Stansbrey, R. J., Maxhimer, R., Periclou, A. P., Mann, A., & Graham, S. M. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0044 · Cited by 77
Feldman, H., Schmitt, F. A., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213859.35355.59 · Cited by 73
Memantine Treatment of Complex Regional Pain Syndrome
Sinis, N., Birbaumer, N., Gustin, S. M., Schwarz, A., Bredanger, S., Becker, S. T., Unertl, K. E., Schaller, H., & Haerle, M. (2007) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e31802f67a7 · Cited by 69
Tinnitus treatment with memantine
Figueiredo, R. R., Langguth, B., de Oliveira, P. M., & de Azevedo, A. A. (2008) · Otolaryngology · doi:10.1016/j.otohns.2007.11.027 · Cited by 66
Memantine in the treatment of binge eating disorder: An open‐label, prospective trial
Brennan, B. P., Roberts, J. L., Fogarty, K. V., Reynolds, K. A., Jonas, J. M., & Hudson, J. I. (2008) · International Journal of Eating Disorders · doi:10.1002/eat.20541 · Cited by 64
Schmitt, F. A., van Dyck, C. H., Wichems, C. H., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213860.35355.d4 · Cited by 62
van Dyck, C. H., Schmitt, F. A., & Olin, J. T. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000203151.17311.38 · Cited by 62
Emre, M., Mecocci, P., & Stender, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14207 · Cited by 59
Grossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000200013 · Cited by 59
Schifitto, G., Yiannoutsos, C. T., Simpson, D. M., Marra, C. M., Singer, E. J., Kolson, D. L., Nath, A., Berger, J. R., & NAVIA, B. A. (2006) · Journal of NeuroVirology · doi:10.1080/13550280600873835 · Cited by 58
Krivoy, A., Weizman, A., Tatsa-Laur, L., Hellinger, N., Zemishlany, Z., & Fischel, T. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.008 · Cited by 57
Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death
Dreyer, E. B., Zhang, D., & Lipton, S. A. (1995) · Neuroreport · doi:10.1097/00001756-199504190-00029 · Cited by 57
Neuroprotective effect of memantine combined with topiramate in hypoxic–ischemic brain injury
Liu, C., Lin, N., Wu, B., & Qiu, Y. (2009) · Brain Research · doi:10.1016/j.brainres.2009.05.071 · Cited by 56
Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage
Sinn, D.-I., Lee, S., Chu, K., Jung, K., Song, E., Kim, J., Park, D.-K., Kim, M., & Roh, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.10.050 · Cited by 52
Glutamate Antagonists Seem to be Slightly Effective in Psychopharmacologic Treatment of Autism
Niederhofer, H. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000270082.30500.69 · Cited by 51
Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition
Jung, K., Chu, K., Lee, S., Park, H.-K., Kim, J.-H., Kang, K., Kim, M., Lee, S. K., & Roh, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.081 · Cited by 48
The use of memantine in dementia with Lewy bodies
Sabbagh, M. N., Hake, A. M., Ahmed, S., & Farlow, M. R. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7403 · Cited by 46
Jones, R. W., Bayer, A. J., Inglis, F., Barker, A., & Phul, R. K. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1752 · Cited by 44
Memantine in Vascular Dementia
Möbius, H. J., & Stöffle, A. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009219 · Cited by 43
Muhonen, L. H., Lahti, J. M. T., Sinclair, D., Lönnqvist, J. K., & Alho, H. (2008) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-3-20 · Cited by 43
Pilot Trial of Memantine in the Treatment of Posttraumatic Stress Disorder
Battista, M., Hierholzer, R., Khouzam, H., Barlow, A., & O’Toole, S. K. (2007) · Psychiatry · doi:10.1521/psyc.2007.70.2.167 · Cited by 42
Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone
Rojas, J. C., Saavedra, J. A., & Gonzalez-Lima, F. (2008) · Brain Research · doi:10.1016/j.brainres.2008.04.001 · Cited by 40
Memantine enhances autonomy in moderate to severe Alzheimer's disease
Rive, B., Vercelletto, M., Delamarre-Damier, F., Cochran, J. M., & François, C. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1112 · Cited by 40
Morè, L., Gravius, A., Nagel, J., Valastro, B., Greco, S., & Danysz, W. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283123cad · Cited by 38
In vitro galantamine-memantine co-application: Mechanism of beneficial action
Zhao, X., Marszalec, W., Tóth, P. T., Huang, J. C., Yeh, J. Z., & Narahashi, T. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.007 · Cited by 37
Ferris, S. H., Schneider, L. S. S., Farmer, M. V., Kay, G. G., & Crook, T. H. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1711 · Cited by 37
Memantine for Moderate to Severe Alzheimerʼs Disease
&NA; (2003) · Journal of Neuroscience Nursing · doi:10.1097/01376517-200312000-00011 · Cited by 36
Ott, B. R., Blake, L. M., Kagan, E., Resnick, M., & for the Memantine MEM-MD-11AB Study Group (2007) · Journal of Neurology · doi:10.1007/s00415-006-0374-x · Cited by 35
A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome.
Rustembegovic, A., Kundurović, Z., Šapčanin, A., & Sofic, E. (2003) · PubMed · Cited by 34
Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F. M., & Günay, İ. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100875 · Cited by 34
Lapchak, P. A. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.093 · Cited by 34
Collins, E. D., Vosberg, S. K., Ward, A. S., Haney, M., & Foltin, R. W. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.3.228 · Cited by 25
[Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].
Fischer, P. A., Jacobi, P., Schneider, E. M., & Schönberger, B. (1977) · PubMed · Cited by 23
Thuerauf, N., Lunkenheimer, J., Lunkenheimer, B., Sperling, W., Bleich, S., Schlabeck, M., Wiltfang, J., & Kornhuber, J. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0570-y · Cited by 20
An evaluation of the reinforcing effects of memantine in cocaine-dependent humans
Vosburg, S. K., Hart, C. L., Haney, M., & Foltin, R. W. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.01.020 · Cited by 20
Ito, Y., Nakamura, S., Tanaka, H., Shimazawa, M., Araie, M., & Hara, H. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00050.x · Cited by 16
Memantine normalizes brain activity in the inferior frontal gyrus: A controlled pilot fMRI study
Cerullo, M. A., Nasrallah, H. A., Eliassen, J. C., Adler, C. M., Nasrallah, A. T., & Strakowski, S. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.034 · Cited by 16
Waldemar, G., Hyvärinen, M., Josiassen, M. K., Kørner, A., Lehto, H., & Wetterberg, P. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1979 · Cited by 15
Paskavitz, J., Gunstad, J., & Samuel, J. (2007) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317506294474 · Cited by 5
DAUTZENBERG, P. L. J., Wouters, C. J., & Bootsma, J. E. M. (2006) · International Psychogeriatrics · doi:10.1017/s104161020625347x · Cited by 5
Memantine in the Preventive Treatment of Refractory Migraine
Panagariya, A. (2009) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(09)79069-6 · Cited by 5
Леоновна, Г. Т., Воронина, Т. А., Литвинова, С. А., Al, K., Евгеньевич, К. А., & Alesenko, A. V. (2008) · PubMed · Cited by 5
[Efficacy and safety of memantine in dementia with Lewy bodies].
Levin, O. S., Batukaeva, L. A., Геннадьевна, С. И., & Амосова, Н. А. (2008) · PubMed · Cited by 4
Memantine Treatment of Complex Regional Pain Syndrome: A Preliminary Report of Six Cases
Abram, S. E. (2008) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/s1073-5437(08)70997-5 · Cited by 4
Wenk, G. L., Danysz, W., & Mobley, S. A. (1995) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/s0922-4106(05)80053-7 · Cited by 4
Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Flagged first, then by citations
2 of the 104 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [97]Grossberg GT Manes F Allegri R A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer’s disease. [poster] 133rd Annual Meeting of the American Neurological Association September 21–24, 2008 Salt Lake City, UT, USA Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings This journal is indexed on PubMed Central, MedLine, the American Chemical Society’s ‘Chemical Abstracts Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Cited by
Sorted by citations
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction
Kakuda, T. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.03.010 · Cited by 124
Metadata
- Authors
- Grossberg, G., & Thomas, S.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Grossberg, George
- ORCID
- Grossberg, George
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 4
- Pages
- 367
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC2762361
- OpenAlex
- W2008348302
- Cited by
- 151
- References
- 104
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 3 · 2017: 17 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 10 · 2012: 7
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- memantine, Alzheimer's disease, dementia, NMDA receptor antagonists, drug safety, drug efficacy, cholinesterase inhibitors, vascular dementia, mild Alzheimer's disease, neuroprotection, neuropsychiatric disorders
- MeSH terms
- Alzheimer Disease, Dementia, Humans, Memantine, Severity of Illness Index, Dopamine Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
